Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > Drug Approval & Reimbursement in 2023
Drug Approval & Reimbursement in 2023
-
Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
-
Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
May 17, 2023
-
Japan Approves Mefeego as First Abortion Pill
May 1, 2023
-
Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
-
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
-
Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
March 9, 2023
-
Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
-
Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
-
Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…